Synchron has raised $340M from 48 investors including 3cap, Armyn Capital, Axial Partners, and In-Q-Tel. The company completed a Series D funding round in November 2025 with participation from 12 investors. Apple is working with Synchron to develop devices including iPhones that could be controlled using brain implants and users' thoughts.
Cyborg Score Rationale
Synchron is a well-funded, late-stage biotech company with meaningful clinical validation in brain-computer interfaces and a major tech partnership with Apple. Strong investor backing and recent Series D funding demonstrate confidence in the technology and market opportunity.
Top Insights
Recent Series D funding (November 2025) with 12 investors validates market demand for implantable neurotechnology solutions
Strategic partnership with Apple signals mainstream commercialization pathway for brain-computer interface technology
Focus on minimally-invasive Stentrode delivery via catheter differentiates from competitors pursuing more invasive surgical approaches
Cognitive AI foundation model (Chiral) unveiled at NVIDIA GTC 2025 expands addressable market beyond motor neuroprosthetics
Named Competitors
Neuralink — Brain-computer interface with invasive electrode arrays